Full history for every metric is available with a Kvantra account
Psychemedics Corporation (PMD)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 38 | 21 | 25 | 25 | 22 | 20 | 20 |
| Operating profit | $m | -2 | -2 | |||||
| Net profit | $m | 2 | -4 | -1 | -1 | -4 | -2 | -2 |
| EPS reported | $ | -0.32 | -0.32 | |||||
| Operating cashflow per share | $ | 0.16 | 0.16 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | 0.14 | 0.14 | |||||
| Free cash flow | $m | 1 | 1 | |||||
| Net debt | $m | -1 | -1 | |||||
| Book value equity | $m | 5 | 5 | |||||
| Book value per share | $ | 0.87 | 0.87 | |||||
| Number of shares | m | 5.87 | 5.89 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.56 | 3.03 | |||||
| P/S LTM | x | 0.67 | 0.79 | |||||
| P/FCF LTM | x | 15.61 | 17.83 | |||||
| EV/EBITDA LTM | x | 67.49 | 75.16 | |||||
| EV/Sales LTM | x | 0.65 | 0.73 | |||||
| Earnings Yield LTM | % | -14.16% | -11.88% | |||||
| FCF Yield | % | 6.41% | 5.61% | |||||
| Quality | ||||||||
| ROE | % | -36.28% | -31.54% | |||||
| ROIC | % | -29.20% | -29.20% | |||||
| Operating margin | % | -9.62% | -9.62% | |||||
| Gross margin | % | 36.07% | 36.07% | |||||
| FCF/Sales | % | 4.28% | 4.28% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -10.92% | -10.92% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | -100.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.72 | 0.75 | |||||
| Net Debt/EBITDA | x | -1.31 | -1.31 | |||||
| EBIT/Net interest | x | -72.81 | -72.81 | |||||
| Net debt/market cap | % | -9.19% | -7.76% | |||||
| Net debt/Equity | x | -0.24 | -0.24 | |||||
| Gross debt/equity | x | 0.23 | 0.23 | |||||
Company overview
Established in 1986 and based in Acton, Massachusetts, Psychemedics Corporation specializes in providing comprehensive drug abuse detection services. The company operates across the United States, Brazil, and various international locations, employing hair sample analysis to identify a broad spectrum of substances. Their rigorous testing methodology involves both initial screening and confirmatory analysis through mass spectrometry, adhering to recognized industry standards. Psychemedics' analytical capabilities cover a wide array of drugs, including common illicit substances like cocaine, marijuana, and PCP. They also detect various amphetamines, such as ecstasy, eve, and Adderall, along with a comprehensive list of opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. Furthermore, their tests identify synthetic cannabinoids (e.g., K2, Spice, Blaze), benzodiazepines (like Xanax, Valium, and Ativan), nicotine, and Fentanyl. The results of their analyses offer more than just a positive or negative finding; they provide quantitative data indicating the approximate amount of drug consumed. Crucially, the tests also yield historical information that can reveal an individual's drug use patterns over an extended period. Psychemedics serves a diverse clientele, including employers seeking applicant and employee drug screening, treatment professionals, law enforcement agencies, school administrators, and parents concerned about potential substance use by their children.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Psychemedics Corporation (PMD)
Established in 1986 and based in Acton, Massachusetts, Psychemedics Corporation specializes in providing comprehensive drug abuse detection services. The company operates across the United States, Brazil, and various international locations, employing hair sample analysis to identify a broad spectrum of substances. Their rigorous testing methodology involves both initial screening and confirmatory analysis through mass spectrometry, adhering to recognized industry standards. Psychemedics' analytical capabilities cover a wide array of drugs, including common illicit substances like cocaine, marijuana, and PCP. They also detect various amphetamines, such as ecstasy, eve, and Adderall, along with a comprehensive list of opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. Furthermore, their tests identify synthetic cannabinoids (e.g., K2, Spice, Blaze), benzodiazepines (like Xanax, Valium, and Ativan), nicotine, and Fentanyl. The results of their analyses offer more than just a positive or negative finding; they provide quantitative data indicating the approximate amount of drug consumed. Crucially, the tests also yield historical information that can reveal an individual's drug use patterns over an extended period. Psychemedics serves a diverse clientele, including employers seeking applicant and employee drug screening, treatment professionals, law enforcement agencies, school administrators, and parents concerned about potential substance use by their children.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free